Bristol-Myers Squibb Company (BMY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $61.15. The rating moved from Neutral to Oversold on September 30, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$61.15
• Last changeMoved from Neutral to Oversold on September 30, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - General

See all oversold Healthcare stocks →

AI analysis

Bristol-Myers Squibb Company (BMY) presents a stable large‑cap pharma profile supported by diversified commercial revenues, an active late‑stage pipeline and capacity for disciplined M&A and shareholder returns. Current market tone is cautious, favoring defensive healthcare names, which should provide some near‑term support, while late‑stage biologics data in the sector bolster specialty pharma outlook. However, policy risk around Medicare negotiation, intensifying therapeutic competition and the potential for pipeline or regulatory setbacks create meaningful downside scenarios that warrant monitoring.

Key factors

• Large, diversified commercial portfolio with steady cash flows and an established presence in oncology and specialty medicines
• Deep late-stage pipeline and recent positive read-throughs in rare-disease biologics that support specialty pharma outlook
• Defensive sector positioning amid risk-off flows, which tends to support demand for large-cap pharma exposure
• Financial flexibility and scale to pursue targeted M&A, R&D investment, and maintain shareholder returns (dividend/share buybacks)
• Insider activity (Form 4 filings) showing modest positive/neutral signals, suggesting internal confidence or routine compensation activity

Risks

• Medicare drug‑price negotiation and broader payer pressure (IRA and related policy actions) that can compress pricing and access for higher-cost therapies
• Intensifying competitive dynamics in adjacent therapeutic areas (including GLP-1/amylin combos and other novel entrants) that could pressure market share and pricing
• Clinical or regulatory setbacks in late‑stage programs that could materially affect future revenue growth
• Patent expirations, biosimilar erosion, or pricing concessions in key franchises
• Macro-driven market volatility, supply-chain disruptions, or geopolitical headlines that could depress near-term multiples despite defensive positioning

Latest MarketMoodz coverage

• Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
• Takeda’s AI-Designed Zasocitinib Tops Sotyktu in Phase 32026-06-11
• Space-made drugs: PIL-BOX pushes pharma into orbit2026-06-09
• Sanofi, Owkin Deepen AI Tie with Agentic AI Initiative2026-06-05
• Bristol Myers, Hengrui Team Up — China Emerges as R&D Hub2026-05-15

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.